PaxVax is a privately held, venture capital backed biotech vaccine company. Established in 2007, in response to the threat of pandemic outbreak throughout the world, our mission is to develop and commercialize innovative and socially responsible vaccines against infectious diseases.

PaxVax has a clinical stage product portfolio including a cholera vaccine entering Phase 3, and a pandemic H5N1 influenza vaccine entering Phase 2. Our proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target any protein antigen. This technology allows us to provide accessible, affordable and effective vaccines across the globe.

Our company also has contracts and grants supporting the development of vaccines for HIV and anthrax; as well as the characterization of a novel cell substrate, A549 cells, for vaccine
production.

We currently have forty five employees between our office headquarters in Menlo Park, California and R&D laboratories and licensed GMP production facility in San Diego, California.